ArticleIDCases2025
Management of
Article in IDCases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Alveolar Echinococcosis in the Early 2020s: A Systematic Review.Pathogens (Basel, Switzerland) · 2026Pooled it
- Abdominopelvic hydatid disease during pregnancy: a systematic review of the literature.Frontiers in global women's health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alveolar echinococcus (AE) is a zoonosis caused by the Case: A 20-year-old female became pregnant ten months after the initial diagnosis of AE with peritoneal dissemination. After discussion of risks and benefits of continuing with the pregnancy, the decision was made to closely monitor the patient with monthly liver ultrasound exams. Due to potential risk for teratogenicity, she was advised to hold albendazole treatment during first trimester with the understanding that she would restart if lesions formed or enlarged. The patient chose to continue abstaining from albendazole for the entire pregnancy. During the albendazole-free period, no new cystic growths or enlargement of existing cysts were observed in close follow-up. She had an uncomplicated delivery at 39.5 weeks via Cesarean section. Albendazole was restarted following delivery, and due to concerns about infant albendazole exposure, formula feeding was preferred over breastfeeding. Conclusion: AE poses many management challenges in pregnant people. Effectively managing these challenges requires in-depth discussion about potential risks of withholding or continuing treatment, a shared decision-making approach, and close disease monitoring throughout the pregnancy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.